NASDAQ:DNLI
Denali Therapeutics Inc.
Denali Therapeutics Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$422.1M, and the diluted share count rose 5.0%.Summary generated from Denali Therapeutics Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−45.7%
Debt / equityn/a
Free cash flow−$422.1M
FCF marginn/a
Share count change+5.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 49 | 108 | 331 | 0 | 0 |
| Operating income | −296 | −341 | −197 | −487 | −555 |
| Net income | −291 | −326 | −145 | −423 | −513 |
| Free cash flow | −220 | −263 | −371 | −364 | −422 |
Recent filings
- 4Insider transaction report
Sep 9, 2026 - 4Insider transaction report
Sep 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KCompletion of an acquisition or disposition
Jul 28, 2026 - 8-KEntry into a material agreement
Jun 18, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026 - 8-KRegulation FD disclosure
May 22, 2026